** Shares of Janux Therapeutics JANX.O gain >7% on Thurs after co raises more equity than targeted in follow-on offering
** JANX shares rise as much as 7.3% to $71.71, surpassing prior record intraday high of $71.25 hit on Tues. Stock last up 1.4% at $67.79
** Co late Weds announced pricing ~5.6 mln shares, including pre-funded warrants to buy 238,095 shares, at $63 for $350 mln gross proceeds
** Shares soared 49% to close at $59.86 on Tues, a day after data for co's drug to treat prostate cancer exceeded expectations in early-stage study
** After the bell Tues, co commenced $300 mln offering
** Co plans to use net offering proceeds to advance clinical development of its internal pipeline products, and for general purposes
** BofA, TD Cowen, Stifel and William Blair are jt bookrunners
** Prior to offering, co had ~52.3 mln shares outstanding for about $3.5 bln market cap
** Stock ended 2023 at $10.73
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。